Opioid vaccine trial aims to block Drug's brain effects

NCT ID NCT04458545

Recruiting now Disease control Sponsor: New York State Psychiatric Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a vaccine that helps the body produce antibodies against oxycodone, a commonly abused prescription opioid. The goal is to reduce the drug's ability to reach the brain and lower its pleasurable effects. The trial involves 45 adults with opioid use disorder and focuses on safety, immune response, and drug liking. It is not a cure but a new tool to support ongoing treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

Clinilabs Drug Development Corporation
RECRUITING

Eatontown, New Jersey, 07724, United States
New York State Psychiatric Institute: Division on Substance Use Disorders
ACTIVE_NOT_RECRUITING

New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.